Works by Melemed, Allen S.

Results: 4

Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model.
Published in:
Statistics in Medicine, 2013, v. 32, n. 2, p. 240, doi. 10.1002/sim.5487
By:
- Fu, Haoda;
- Wang, Yanping;
- Liu, Jingyi;
- Kulkarni, Pandurang M.;
- Melemed, Allen S.
Publication type:
Article
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Published in:
Neuro-Oncology, 2024, v. 26, p. S173, doi. 10.1093/neuonc/noae031
By:
- Arrillaga-Romany, Isabel;
- Lassman, Andrew;
- McGovern, Susan L;
- Mueller, Sabine;
- Nabors, Burt;
- van den Bent, Martin;
- Vogelbaum, Michael A;
- Allen, Joshua E;
- Melemed, Allen S;
- Tarapore, Rohinton S;
- Wen, Patrick Y;
- Cloughesy, Timothy
Publication type:
Article
Extranodal spread of anaplastic large cell (CD30+) lymphoma presenting as a cutaneous perivascular infiltrate.
Published in:
Journal of Cutaneous Pathology, 1996, v. 23, n. 4, p. 323, doi. 10.1111/j.1600-0560.1996.tb01305.x
By:
- Derringer, Gregory A.;
- Cotton, Jenny P.;
- Melemed, Allen S.;
- Treadwell, Patricia A.;
- Hood, Antoinette F.
Publication type:
Article
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
Published in:
2018
By:
- Smit, Egbert F.;
- Garon, Edward B.;
- Reck, Martin;
- Cappuzzo, Federico;
- Bidoli, Paolo;
- Cohen, Roger B.;
- Gao, Ling;
- O’Brien, Lisa M.;
- Lee, Pablo;
- Zimmermann, Annamaria;
- Ferry, David R.;
- Melemed, Allen S.;
- Pérol, Maurice;
- O'Brien, Lisa M
Publication type:
journal article

Works by Melemed, Allen S.

Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model.

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Extranodal spread of anaplastic large cell (CD30+) lymphoma presenting as a cutaneous perivascular infiltrate.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.